A hydrolytically stable oxo-rhenium(<scp>v</scp>) antitumor agent for synergistic combination therapy with cisplatin: from synthesis and mechanistic studies to toxicity assessment in zebrafish-Reference-Cited by-同舟云学术

A hydrolytically stable oxo-rhenium(v) antitumor agent for synergistic combination therapy with cisplatin: from synthesis and mechanistic studies to toxicity assessment in zebrafish

Published:2023 Issue:22 Volume:10 Page:6711-6727
ISSN:2052-1553
Container-title:Inorganic Chemistry Frontiers
language:en
Short-container-title:Inorg. Chem. Front.

Author:

Vaidya Shreyas P.¹,M Manikandan¹^ORCID,Chhatar Sushanta¹,Dey Saurabh²^ORCID,Patra Chinmoy²,Patra Malay¹^ORCID

Affiliation:

1. Medicinal Chemistry and Cell Biology Laboratory, Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai, Maharashtra 400005, India

2. Department of Developmental Biology, Agharkar Research Institute, G G Agarkar Road, Pune, Maharashtra 411004, India

Abstract

A hydrolytically stable oxo-Re(v) complex presents potent in vitro antitumor activity as a single agent or in combination with cisplatin and negligible toxicity in zebrafish.

Funder

Department of Biotechnology, Ministry of Science and Technology, India

Department of Atomic Energy, Government of India

Tata Institute of Fundamental Research

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/QI/D3QI01653F

Reference73 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries